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Acute Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation.
Although this process is thought to consist of several phases, T-cell activation plays a critical role in the pathogenesis of acute
GVHD. To become eﬃcient eﬀectors, T-cells require additional costimulation after T-cell receptor signaling. A number of
molecules are involved in costimulation of T-cells such as CD28, CD40L, CD30, OX40, 4-1BB, ICOS, and LIGHT. The system
is regulated by inhibitory molecules, CTLA-4, and PD-1. There is experimental evidence that those molecules are implicated in
the pathogenesis of GHVD. We describe how these molecules are involved in acute GVHD and how the blockade of costimulatory
molecules may have potential implications for the treatment of patients with acute GVHD.
1.Introduction
Acute graft-versus-host disease (GVHD) remains the most
important cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation [1]. The recent
advances in the pathogenesis of this complication have not
been fully translated into an improved treatment for the
patients. Only a few immunosuppressive agents are available
for the treatment of acute GVHD and thus, new, more
selective treatments are needed.
AcuteGVHDisanimmune-mediated diseasethatresults
from a complex interaction between immune cells from
both, the donor, and recipient. The pathophysiology of this
process is thought to consist of several phases: (1) priming of
the immune response through the conditioning treatments
that induce inﬂammation, and secondary activation of
antigen presenting cells (APCs) and T-cells, (2) activation
of T-cells which leads to an expansion of eﬀector cells, and
ﬁnally, (3) traﬃcking of activated T-cells to target tissues
where inﬂammation and tissue destruction occurs [1].
Donor-derived T-cells are considered to be the main
eﬀector cells mediating acute GVHD. Donor T-cells are
able to recognize HLA disparities between the donor and
recipient, which is directly related to the development of
acute GVHD. Furthermore, recipients of HLA identical
transplants can still develop acute GVHD due to diﬀerences
in the so-called minor histocompatibility antigens [2].
T-cell activation in response to an alloantigen requires
two stimulatory signals [3]. The ﬁrst signal happens through
the T-cell receptor (TCR), which recognizes the antigen
and is HLA restricted. This signal is necessary but not
suﬃcient to induce a full T-cell activation. Signal 2, known
as costimulation, is necessary to induce T-cell proliferation,
cytokine secretion, and eﬀector function after TCR activa-
tion. This costimulation signal is mediated by a number
of molecules mostly expressed on APCs that include the
B7-CD28 family, the TNF receptor family, and adhesion
molecules such as LFA-1. In addition, the costimulatory
systemistightlyregulatedbyasubsetofinhibitorymolecules
such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and
programmed death-1 (PD-1) [4]( Table 1). Costimulatory
signals are essential for the majority of T-cell functions;
in the absence of a proper costimulation T-cells become
unresponsive or die because of apoptosis. Studies performed
in experimental models of acute GVHD have shown that
costimulatory molecules play a pivotal role in the initiation
of acute GVHD [5]. This paper will focus upon the role of
T-cell costimulatory molecules in GVHD and how these data
could be translated into the development of new therapies
for patients with acute GVHD.2 EURASIP Journal on Bone Marrow Research
Table 1: T-cell costimulatory/inhibitory molecules and their ligands.
Molecules Cell expression Ligand Cell expression
Stimulatory
CD28 T-cells CD80 (B7-1) APCs
CD86 (B7-2) APCs
CD40 APCs CD40L (CD154) T-cells (CD4+)
OX40 (CD134) T-cells OX40L APCs
4-1BB (CD137) T, NK cells 4-1BBL APCs
ICOS T-cells ICOSL (B7h) APCs
LIGHT T, NK cells HVEM T-cells, APCs
CD30 T, NK, B-cells CD30L (CD153) T-cells (CD4+)
Inhibitory
CTLA-4 (CD152) T-cells CD 80, CD86 APCs
PD-1 T-cells PDL1 (B7H1) DCs, T-cells
PDL2 (B7DC) Monocytes
APCs: antigen presenting cells.
2.B7/CD28/CTLA-4 Pathway
The CD28 receptor and its ligands, the B7 family, are the
ﬁrst signaling pathway necessary for T-cell costimulation
[6]. CD28 is a receptor constitutively expressed on T-cells
(both CD4+ and CD8+) and NK cells. Ligation of CD28 after
TCR signaling enhances T-cell proliferation and cytokine
secretion. The main ligands of CD28 are the B7 family,
with B7-1 (CD80) and B7-2 (CD86) being the two most
important molecules. CD80 and CD86 are expressed on
APCs, mostly B-cells and dendritic cells, and the expression
is induced after those cells are activated. Experimental
studies have shown that proinﬂammatory signals generated
following the conditioning treatment upregulate CD80 and
CD86 expression in GVHD target tissues, establishing the
rationale for the CD28/B7 pathway blockade in the GVHD
treatment.
Studies in GVHD animal models have demonstrated the
potential utility of antibodies blocking B7-1 and B7-2 in
acute GVHD. Animals receiving both anti-CD80 and CD86
antibodies experienced lower mortality due to acute GVHD,
and this was mediated by inhibition of donor CD4+ and
CD8+ T-cell expansion [7, 8]. Those studies also showed that
expression of B7-1 on donor CD4+ T-cells was critical for
GVHD development, and hence, the treatment with anti-
B7 antibodies also contributed to reduce GVHD not only
by targeting B7 expression on the APCs but also by a direct
eﬀect on CD4+ T-cells. However, GVHD treatment based
upon B7 blockade was far from perfect and other studies
focused on CD28. By using CD28-deﬁcient mice models it
has been shown that T-cells were able to induce less severe
GVHD, providing evidence that GVHD depends, at least
partially, on signaling through CD28 [9]. In this scenario,
selective targeting of CD28 with a blocking antibody inhibits
T-cell donor expansion and signiﬁcantly prevents GVHD in
murinemodels.Moreimportantly,inhibitionofGVHDwith
anti-CD28 proved to be superior to the treatment with anti-
B7 antibodies. To add complexity to the involvement of the
CD28 pathway in GVHD, recent studies have focused upon
the use of superagonistic anti-CD28 antibodies [10]. These
molecules reduce GVHD mostly by preferential targeting
of regulatory T-cells (Tregs) over conventional T-cells, thus
preserving the graft versus tumor reaction (GVT) [11]. A
combination of CD28 stimulation plus rapamycin was also
showntopreventacuteGVHDinanimalmodels,conﬁrming
previous data suggesting that, at least in mice, Tregs require
CD28 costimulation to maintain their suppressive functions
[12].
CTLA-4 is a molecule that acts along the CD28-B7
stimulation pathway by inhibiting T-cell alloreactivity [4].
Once T-cells are activated, CTLA-4 is upregulated and binds
to B7 proteins (CD80 and CD86) with higher aﬃnity than
CD28, thus resulting in inhibition of T-cell activation. A
strategy using CTLA-4 to inhibit GVHD has been tested
in animal models. Infusion of CTLA4-Ig (a soluble fusion
proteincontainingtheextracellulardomainofCTLA4linked
to an IgG Fc region) was able to reduce GVHD in recipients
of mismatched grafts [13]. However, inhibition of GVHD
was not complete and, comparatively, its inhibitory eﬀect on
GVHD was lesser than using anti-CD28 antibodies [8].
The clinical translation of the knowledge of the CD28-
B7-CTLA-4 pathway to the treatment of GHVD in humans
has been scarce, partially because of the high complexity
of this system. Nevertheless, the proof of concept has been
demonstrated in a selected group of patients (n = 12)
receiving a haploidentical marrow graft [14]. To reduce the
elevated risk of acute GVHD in these patients, the donor
marrow was cocultured ex vivo with irradiated mononuclear
cells from the patient in the presence of CTLA4-Ig. The
rationale of this approach was to induce anergy of the
alloreactive donor T-cells, while preserving the GVT eﬀect.
Only three patients developed acute GVHD, which was
successfully treated with steroids in two of them.
A new CTLA4-Ig fusion protein derivative, Abatacept,
inhibits the interaction of B7 proteins with CD28, and
reduces INF-γ and IL-17 secretion. While it is being used
for treating autoimmune diseases, its role in the treatment
of acute GVHD has not been tested so far [15].EURASIP Journal on Bone Marrow Research 3
3.CD40/CD40L Pathway
The CD40-CD40L pathway plays a critical role in the reg-
ulation of both the humoral and cellular immune response
[16]. CD40, a member of the tumor necrosis factor receptor
(TNFR)superfamily,isexpressedonAPCs(B-cells,dendritic
cells and monocytes), and its ligand, CD40L (CD154), is
expressed on activated CD4+ T-cells and a small subset of
CD8+ T-cells. Ligation of CD40 stimulates the expression
of costimulatory molecules on APCs (i.e. CD80, CD86)
and contributes to an eﬀective activation of T-cells. In
addition,CD40-CD40Linteractionsenhancethesecretionof
proinﬂammatorycytokines(i.e.,IL-2,IL-12,andIFN-γ)that
further contributes to the activation of T and NK cells. Ex
vivo blockade of CD4+ T-cells using anti-CD40L antibody
induces tolerance of CD4+ T-cells to host alloantigens and
reduces GVHD, while preserving T-cell responses directed to
those antigens not present during tolerisation [17].
The role of this system in the pathogenesis of GVHD
wasdemonstratedinexperimentalGVHDmodels,wherethe
administration of anti-CD40L antibodies was able to reduce
the lethality of GVHD [18]. When pure T-cell populations
were administered into sublethally irradiated recipients,
anti-CD40L antibodies improved the GHVD caused by
CD4+ T-cells, but not by CD8+ T-cells, consisting with the
preferential expression of CD40L on activated CD4+ T-cells
[19]. However, mechanistic studies on the action of anti-
CD40L antibodies do not support the idea that it only aﬀects
T-cell costimulation. In fact, anti-CD40L antibodies seem to
act primarily through the selective depletion of activated T-
cells, rather than costimulatory blockade [20]. Interestingly,
several studies have shown that blockade of CD40-CD40L
pathway induces Tregs that may contribute to the GVHD
inhibition [21, 22].
Studies comparing the blockade of CD40L versus CD28
pathway have shown that the use of anti-CD40L was signif-
icantly more eﬀective than anti-B-7 antibodies in reducing
GVHD [23]. In addition, experimental studies suggest that
dual blockade of CD40L and CD28 pathway may be useful
in reducing GVHD lethality. In this regard, a selective B7-
CD28 blockade, using CTLA4-Ig plus anti-CD40L blockade
have been shown to reduce GVHD severity and may be more
advantageous than using anti-CD28 antibodies [22].
Another important issue, when using a costimulatory
blockade to improve GVHD, is the preservation of the
GVT eﬀect. In this regard, treatment with anti-CD40L
had a deleterious eﬀect on the GVT reaction in a murine
allogeneic hematopoietic transplantation model, in contrast
to antibodies blocking CD28. The inhibition of the GVT
eﬀect may be due to the inhibitory eﬀects on Th1 and
cytotoxic T-cells and inhibition of IL-12 cytokine secretion
[24].
4. OX40/OX40L Pathway
OX40 (CD134) is a member of the TNFR family and is
expressed on activated CD4+ and CD8+ T-cells. Its ligand,
OX40L, is expressed preferentially on APCs, that is, dendritic
cells and B-cells. Signaling through OX40 induces generates
costimulatory signals resulting in cytokine secretion, Th1
andTh2,andpromotesT-cellproliferationanddevelopment
into memory cells [25].
Studies done in animal models have shown that OX40-
OX40L interactions play an important role in the patho-
genesis of GVHD [26, 27]. T-cells expressing OX40 were
present in lymphohematopoietic organs of rats with GVHD,
and CD4+ and CD8+ T-cells from mice with GVHD showed
upregulation of OX40.
In the clinical setting, studies performed in patients
undergoing allogeneic stem cell transplantation (SCT) have
showed an involvement of OX40 in the development of
GVHD. Thus, in our experience, among a series of activating
and costimulatory T-cell molecules, OX40 was preferentially
upregulated in CD4+ T-cells from patients with acute GVHD
[28]. Other studies have also shown the existence of OX40-
expressing T-cells in patients with acute and chronic GVHD
[29, 30].
The increased presence of OX40+ T-cells in GVHD
models leads to studying how OX40-OX40L blockade could
aﬀect GVHD. The administration of a blocking antibody
against OX40L reduced the GVHD-induced mortality in
irradiated mice receiving MHC-disparate T-cells [27]. In
contrast, agonistic anti-OX40 antibody markedly increased
the mortality in the same model. These results are consistent
with the data showing that OX40-OX40L interactions clearly
accelerate the GVHD when it is preferentially mediated by
CD4+ T-cells.
In humans, in vitro depletion of alloreactive OX40+T-
cells resulted in a T-cell population that has reduced
alloantigen-speciﬁc reactivity while it has retained T-
cell speciﬁcity against third-party antigens including virus
(CMV) and tumor antigens (WT1) [31]. Collectively, all the
preclinical data suggest that interrupting the OX40-OX40L
pathway may be an interesting strategy to modulate GVHD
in patients undergoing allogeneic SCT.
5. 4-1BB/4-1BBL Pathway
4-1BB (CD137) is a member of the TNFR superfamily
with important implications in T-cell costimulation [25].
4-1 BB is rapidly expressed on activated CD4+ and CD8+
T-cells. Its ligand, 4-1BBL, is expressed on APCs, that is,
dendritic cells, B-cells, and macrophages. CD40 is a major
regulator of 4-1BB expression on APCs. When the signal-
ing through the TCR is strong, 4-1BB/4-1BBL interaction
provides costimulatory signals to T-cells, independently of
CD28. Although, in vitro, 4-1BB can activate both CD4+
and CD8+ T-cells, 4-1BB agonistic antibodies preferentially
act on CD8+ T-cells. 4-1BB interaction induces proliferation
and expansion of CD8+ T-cells, upregulation of eﬀector
molecules including perforin and granzyme A, and IL-2
and INF-γ secretion. In addition, 4-1BB prevents T-cell
apoptosis and prolongs T-cell survival. The importance of 4-
1BBinteractionsinregulatinggraft-versus-hostreactionshas
been shown in studies performed in MHC class II disparate
hosts receiving CD4+ T-cells, where the administration of an
agonistic anti 4-1BB antibody induces 100% mortality, as a
resultant of a severe GVHD. In contrast, when the recipients4 EURASIP Journal on Bone Marrow Research
are 4-1BB negative GVHD lethality is largely reduced
[32].
With these data, several groups have explored the poten-
tial eﬀect of 4-1BB blockade in the development of GVHD.
In an acute GVHD murine model, the administration of an
anti-4-1BBL antibody reduced GVHD lethality, and this was
associated with a diminished donor CD8+ T-cell expansion
[33]. In line with these data, treatment of donor T-cells
with anti-4-1BBL antibody reduced GVHD and improved
survival over a standard cyclosporin A + methotrexate
combination in a MHC disparate GVHD model [34].
Collectively, the experimental data indicate that 4-1BB/4-
1BBL blockade can contribute to signiﬁcantively reduce
GVHD.
6. ICOS/ICOS-L Pathway
The inducible costimulator (ICOS) is a member of the CD28
family, and is expressed in activated CD4+ and CD8+ T-cells
[35].Itsligand,ICOSL,alsoknownasB7h,isexpressedonB-
cells, dendritic cells and macrophages. ICOSL is upregulated
by inﬂammatory cytokines such as INF-γ and TNF-α.I C O S
interaction preferentially regulates Th2 cytokine production
(IL-4 and IL-10), specially in the presence of CD28 signaling
[36]. ICOS interaction is responsible for T-cell expansion
and the eﬀector phase of the immune response, in a CD28-
independent fashion. Although the eﬀect of blocking ICOS
interaction was shown preferentially in chronic GHVD
models, consistent with its eﬀects on Th2 diﬀerentiation
[37], studies done in fully allograft GVHD models have
revealed a prominent role in the development of acute
GVHD [23]. Thus, administration of an anti-ICOS antibody
at the time of the SCT was very eﬀective in reducing GVHD
and improving survival in an acute GVHD model. In line
with these data, studies performed in several murine acute
GVHD models have deﬁnitively shown that ICOS blockade
inhibits the expansion of alloreactive T-cells, and strongly
reduced the number of eﬀector cells, preferentially in critical
GHVD target tissues such as skin and intestine, which
suggest that ICOS may also be involved in the regulation
of T-cell homing and homeostasis [38]. A fully human
antibody blocking human ICOS has been developed and
provedtoameliorateGVHDinsevereimmunodeﬁcientmice
grafted with human blood mononuclear cells [39]. Given
the nonredundant roles of the CD28 and ICOS pathway in
T-cell costimulation, strategies combining ICOS blockade
plus CD28 blockade may constitute an attractive strategy for
GHVD modulation in the clinical scenario [40].
7.LIGHT/HVEMPathway
LIGHT, a member of the TNF superfamily and homologous
tolymphotoxins,isinvolvedinT-cellcostimulationandanti-
gen presentation by dendritic cells [25]. LIGHT is expressed
upon activation of CD4+ and CD8+ T-cells, in NK cells,
and is also detected in immature dendritic cells. Although it
has been described in three diﬀerent receptors, the primary
receptor for LIGHT in T-cells is HVEM (Herpes virus entry
mediator),whichisexpressedinrestingT-cells,NKcells,and
dendritic cells. LIGHT provides a costimulatory signal on T-
cells, which is independent of the CD28 pathway, enhances
T-cell proliferation and Th1 cytokine secretion. In addition
to its eﬀects on T-cells, LIGHT contributes to dendritic cell
maturation, enhanced by CD40L, which results in further T-
cell activation.
Several studies have suggested a role for LIGHT in
a l l o r e a c t i v i t y .I na na l l o g e n e i cm i x e dl y m p h o c y t er e a c t i o n
LIGHT interactions enhances T-cell proliferation, while the
absence of LIGHT, in both responders and stimulators,
results in inhibition of proliferation [41]. The involvement
of LIGHT in GVHD has been demonstrated in preclinical
studies showing that blockade of LIGHT with a soluble
r e c e p t o rw a sa b l et or e d u c eG V H Da n di m p r o v es u r v i v a l
[42]. However, this protective eﬀect was only detected when
GVHD was preferentially mediated by CD8+ T-cells, while
completely failed when the model was dependant on CD4+
T-cells. Since acute GVHD in humans is mediated by both
CD4+ and CD8+ T-cells, investigators tested the blockade
of LIGHT combined with CD40L blockade in a murine
GVHD model [43]. Administration of a LIGHT soluble
receptor plus anti-CD40L antibody beginning on day 0 of
the SCT completely prevented acute GVHD and improved
survival. Although this strategy induced a profound state
of tolerance, the fact that alloantigen-speciﬁc T-cells were
rendered anergic complicates its translation to the clinical
scenario due to the lost of the GVT eﬀect.
8.CD30/CD30L Pathway
CD30, a member of the TNFR superfamily, is expressed
on activated T-cells, NK cells, and B-cells [25]. Its lig-
and, CD30L (CD153), is expressed on resting B-cells and
activated T-cells. Engagement of CD30 in the presence of
TCR stimulation enhances T-cell proliferation and cytokine
production. Although initial analysis suggested a role for
CD30 on Th2 development, studies have shown a role
of CD30 as a T-cell costimulatory molecule involved in
both Th1 and Th2 immune response [44]. CD30L induces
proliferation of T-cells when they are previously treated
with agonistic anti-CD3 antibodies. CD30L is also found
in areas of T-cell and B-cell contact, and provides signals
for B-cell growth and diﬀerentiation. CD30-deﬁcient mice
have an increased autoreactivity, and in humans, alloreac-
tive T-cells preferentially reside within the CD30+ T-cell
subset.
The involvement of the CD30 system in GVHD has been
demonstratedinexperimentalmodels.MicereceivingCD30-
negative MHC class II disparate T-cells had longer survival
compared to animals receiving wild-type (CD30+) T-cells.
Consisting with this data, administration of a blocking anti-
CD30L antibody improved survival in mice after receiving
MHC disparate CD4+ T-cells [45].
9.PD-1/PD-1L Pathway
Programmed death-1 (PD-1), a member of the immu-
noglobulin superfamily, is expressed on activated T-cells,
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PD-1 is a co-inhibitor of T- and B-cell responses [46]. Two
ligands have been shown to interact with PD-1: PD-L1, also
known as B7-H1, is a member of the B7 family, and is
expressedondendriticcellsandactivatedT-cells;PD-L2,also
termed B7-DC, and is expressed on resting monocytes. Both
ligands are expressed in some nonlymphohematopoietic
tissues.
In vivo studies have shown that the main role of PD-1
is to inhibit T-cell responses [47]. Studies to address if this
molecule had a role in the pathogenesis of acute GVHD
showed an increase in PD-1 inﬁltrating cells in GVHD target
organs (intestine, liver) in murine models receiving full
MHC disparate T-cells. PD-1 blockade by administration
of anti-PD-1 antibodies resulted in acceleration of GVHD
andenhancedmortality,mostlymediatedbyIFN-γ secretion
from donor T-cells [48]. In line with this, experimental stud-
ies using T-cells from PD-1 knockout mice have revealed an
enhanced capacity to induce GVHD. Thus, the PD-1/PD-L
pathway seems to be an important mediator of GVHD.
Collectively, these data suggest that agonistic antibodies
to PD-1 may represent a novel strategy for preventing
GVHD.
10. Conclusions
T-cell costimulatory molecules play a critical role in the
development of acute GVHD. In addition to the exten-
sively studied CD28, other molecules have been ultimately
implicated in GVHD. In particular, several members of the
TNFR family (CD40, OX-40, 4-1BB) have relevant roles
in T-cell activation and contribute to the development of
acute GVHD in humans; monoclonal antibodies directed to
these molecules are being developed to use in the clinical
setting. A critical issue is to develop therapeutic strategies
that, while blocking alloreactivity, do not compromise the
GVT eﬀect. In line with this, the blockade of critical T-
cell costimulatory molecules such as CD40L and 4-1BBL,
although potentially useful for reducing GVHD severity,
may severely compromise the GVT eﬀect which may pre-
clude their use in the clinical practice. However, the fact
that the blockade of molecules such as OX-40L did not
signiﬁcantly aﬀect the GVT in experimental models, and in
vitro depletion of OX40L+ T-cells did not aﬀect to third-
party allospeciﬁc T-cells makes this molecule an interesting
target for prevention or treatment of acute GVHD. On the
other hand, the better understanding of the mechanism of
molecules involved in counter regulation of T-cell activation
(i.e., CTLA-4 and PD-1) makes these molecules attractive
targets for GVHD therapy. It is likely that a CTLA-4
fusion protein will be tested in patients with acute GVHD
soon, as it is already used in patients with autoimmune
diseases.
In conclusion, in the next years new monoclonal anti-
bodies and inhibitors of critical costimulatory molecules
will increase the therapeutic strategies for the prevention
or treatment of patients with acute GVHD after allogeneic
stem cell transplantation. It is expected that these new
therapeutic strategies will help to reduce the mortality of this
complication.
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